Beranda › Mielofibrosis › Illinois
Uji klinis Mielofibrosis di Illinois
7 studi untuk Mielofibrosis mencari peserta di lokasi di Illinois.
Kota di Illinois
Teks studi resmi (Bahasa Inggris)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- University of Chicago, Chicago
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04176198A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- University of Chicago Comprehensive Cancer Center, Chicago
- UC Comprehensive Cancer Center at Silver Cross, New Lenox
- University of Chicago Medicine-Orland Park, Orland Park
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06661915A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- University of Chicago Medical Center, Chicago
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07008118Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
Menerima pesertaFase 1
Usia 13 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT04771572MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
- MPN Research Foundation, Chicago
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jan 2026 · NCT07362225Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
- The University of Chicago, Chicago
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Des 2025 · NCT03326310SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.